PANCREATIC AND LUNG CANCERS DRIVEN BY MUTATIONS IN THE CANCER GENE KRAS
Dr Mara Zeissig, Group Head, T Cell Immunotherapy Laboratory
Tumour Inflammation and Immunotherapy Program
SAiGENCI – South Australian immunoGENomics Cancer Institute, Australia
RESEARCHER PROFILE
Filmed in Adelaide, Australia | December 2025
Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors).
Dr Zeissig obtained her PhD at the University of Adelaide in 2020 with Prof Andrew Zannettino, where her research focused on the role of chemokine receptor CCR1 in the dissemination of the hematological malignancy multiple myeloma. She then undertook postdoctoral studies at Monash University with Prof Tony Tiganis, focusing on the role of protein tyrosine phosphotases PTPN2 and PTP1B on anti-tumour immunity in melanoma, breast, colon and liver cancers. In 2022 she joined the lab of Prof Kate Sutherland at WEHI. Here she conducted sophisticated CRISPR-Cas9 in vitro and in vivo screening to identify genetic determinants that influence response to KRAS inhibitors, and to identify novel immunotherapy targets in KRAS-mutant lung cancer. Her research has been published in high-impact journals including Science Advances (2022) and Cancer Discovery (2022). Dr Zeissig has been the recipient of numerous career awards and grants, including a Victorian Cancer Agency ECR Fellowship (2023-2026) and a Cure Cancer Research Grant (2023).
Immunotherapies such as CAR T cell therapy or Immune checkpoint inhibitors all harness the ability of cytotoxic T cells to recognise and kill tumour cells. However, approx. 80% of solid cancer patients do not respond to immunotherapy. This is due to both tumour intrinsic and extrinsic evasion mechanisms, the most crucial of these being 1) the immunosuppressive microenvironment that leads to T cell exhaustion and 2) loss of antigen and/or checkpoint ligand expression on tumour cells rendering the tumour unrecognisable by T cells. Importantly, there may be additional, undiscovered immune evasion mechanisms that could be exploited for immunotherapy.
Dr Zeissig’s lab is focused on understanding how cancers evade the immune system to identify new ways to enhance response to immunotherapy. In particular, her team work on lung and pancreatic cancers driven by mutations in the cancer gene KRAS. They utilise a range of tools including genetically engineered preclinical models of cancer, analysis of immune cell subsets, single-cell profiling and molecular biology techniques. They also harness large-scale genetic screening using CRISPR-Cas9 technology to find previously unknown targets and mechanisms that regulate response to immunotherapy.
Source: Supplied
https://orcid.org/0000-0003-3264-6546
-
At the frontier of human cellular neuroscience research
Associate Professor Cedric Bardy is the Director of The Laboratory for Human Neurophysiology, Genetics & Stem Cells, located at SAHMRI. South Australia.
His current research uses preclinical, patient-derived cell models to test innovative therapeutic strategies, with a current focus on Parkinson’s disease, brain cancer and childhood dementia (Sanfilippo syndrome).
His work has established a platform to facilitate the discovery and validation of treatments for brain disorders. Their research is at the frontier of human cellular neuroscience research and translational applications that benefit global public health.
-
Vision impairment in children and the impact on children and their families
Dr Sue Silveira holds a conjoint academic position with Macquarie University and is the Course Director for their Master of Disability Studies, which is administered and delivered by NextSense Institute in affiliation with the University. She teaches in the areas of vision impairment and disability, and aims to share her knowledge while learning from others, especially people who are blind or have low vision and their families.
-
Impact of NextSense Institute Research in the field of sensory disabilities
NextSense has a 165 year history of providing services and education for individuals with sensory impairments. With the support of donations, NextSense provides vital support for children and adults, more cochlear implants than any other service in Australia, and is a world leader for research, technology and professional education in the fields of visions and hearing loss.
NextSense clinicians are actively involved in a number of leading research projects—both independently and in collaboration with local and international organisations. The NextSense Institute, part of NextSense is Australia’s leading centre for research and professional education in the field of sensory disabilities.
